RP Cure Tracker

Trials / NCT03845218

Retinitis Pigmentosa Clinical Measures and Repeatability Testing of Potential Outcome Measures

Completed Observational Natural history / observational

Sponsor
National Eye Institute (NEI)
Treatment
Not listed
Gene
Not stated
Conditions
Retinitis Pigmentosa
Ages
12 Years to 100 Years
Enrollment
49 participants
Started
2019-09-27
Main results expected
2023-07-19
Results posted
Not yet
Record last updated
2026-09-17

What the study is testing

Background:

Retinitis pigmentosa (RP) is a group of blinding eye diseases. It is caused mostly by mutations in photoreceptor-expressed genes. RP affects about 2 million people globally. There is no cure, but treatment and diagnosis can be guided by certain tests. Researchers want to see how well these tests capture stages of RP.

Objectives:

To find out how well certain tests track changes in retinitis pigmentosa.

Eligibility:

People ages 12 and older with RP

Healthy volunteers ages 18 and older with no evidence of RP

Design:

Participants will be screened in another protocol.

Participants will have 2 visits about 6 weeks apart. Both will include all the tests below. Each visit will last 5-6 hours, or a visit can be split into 2 days.

Participants will give their medical and eye history.

Participants will have an eye exam. Their pupils will be dilated with eye drops.

Participants will give blood samples.

Pictures of participants retinas will be taken. Their retinas will be measured.

Participants will take several eye tests. They will:

Sit in a dark room and press a button when they see lights.

View a bright background then press a button when they see lights.

Look into a bowl and press a button when they see lights.

Sit in the dark with their eyes patched. Then they will take eye-numbing drops and wear contacts as lights flash. A small electrode taped to their forehead will record signals from their retinas.

Minors will give written consent to stay in the study when they turn 18. After the study ends, they may also be asked to give consent for researchers to continue to use their study information.

Where it runs

United States (1)

Open on ClinicalTrials.gov for contacts and eligibility